TECHNOLOGY

AUR-1001 – MODIFIED ANTI-ß₂ GP1 MONOCLONAL ANTIBODY

First specific treatment for Anti Phospholipid Syndrome (APS)

AUR-1001 was engineered by world experts of APS. Its activity on prevention of thrombus formation and clinical manifestations of APS has been demonstrated in animals and results published in international peer reviewed journal.

• Primary when it is not associated with any other condition or underlying reason
• Secondary when it is associated with Systemic Lupus Erythematosus, other autoimmune disorders or an underlying reason such as infections or medications.